(78 days)
Not Found
No
The device is a physical examination glove and the summary does not mention any software, algorithms, or AI/ML capabilities.
No
Therapeutic devices are generally defined as those used to treat, cure, mitigate, or prevent disease. This device is an examination glove primarily intended for preventing contamination between patient and examiner, which is a barrier function, not a therapeutic one.
No
Explanation: This device is a medical glove designed to prevent contamination and protect the examiner from certain drugs. Its function is protective and not to diagnose any condition or disease.
No
The device is a physical glove, not software. The description details physical properties, materials, and performance testing related to a tangible product.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information about a person's health. This information is used for diagnosis, monitoring, or screening.
- Device Intended Use: The intended use of this device is clearly stated as a "disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner." This is a barrier device used for protection, not for analyzing biological specimens.
- Lack of IVD Characteristics: The description and performance studies focus on the physical properties of the glove, its ability to prevent permeation by certain drugs, and its biocompatibility. There is no mention of analyzing biological samples, detecting analytes, or providing diagnostic information.
This device is a medical glove, specifically an examination glove and a specialty chemotherapy glove, designed for personal protection and preventing contamination.
N/A
Intended Use / Indications for Use
Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentaryl Citrate, and Select Other Drugs is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.
These gloves were tested for use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs as per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.
Product codes (comma separated list FDA assigned to the subject device)
LZA, LZC, QDO, OPJ
Device Description
Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs are Class I Patient Examination Gloves and Specialty Chemotherapy Gloves. They are ambidextrous and come in different sizes - Extra Small, Small, Medium, Large, Extra Large, Extra Extra Large. Gloves meet the specification of ASTM D6319- 19 and have been tested for resistance to permeation by chemotherapy drugs, Fentanyl Citrate, and select other drugs as per ASTM D6978-05(2019). The gloves are single use, disposable, and provided non-sterile.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
hand or finger
Indicated Patient Age Range
Not Found
Intended User / Care Setting
medical purposes
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical tests were conducted to verify that the proposed device met all design specifications. The test results demonstrated that the proposed device met the performance criteria with the following standards:
- ASTM D6319-19: Physical Dimensions (Length, Palm Width, Thickness) and Physical Properties (Before aging: Tensile strength, Ultimate elongation; After aging: Tensile strength, Ultimate elongation) - All Passed.
- ASTM D6319-19, ASTM D5151-19: Water leak test (G-I, AQL 2.5 (ISO 2859-1)) - Passed.
- ASTM D6319-19, ASTM D6124-06 (2017): Powder Residue (Max 2mg/glove) - Passed.
- ASTM D6978-05 (2019): Permeation by Chemotherapy Drugs and Fentanyl Citrate - Refer to Table 1 from the Indications for Use section (numerous drugs tested with minimum breakthrough detection times ranging from 0 minutes to >240 minutes, with warnings for Carmustine and Thio Tepa).
- ISO 10993-10:2021: Skin Sensitization - No Skin sensitization; The sample extract elicits no sensitization reactions under the test conditions.
- ISO 10993-23:2021: Irritation - No Skin irritation; Under the conditions of this study, the irritation response category of the test article is classified as Negligible for polar extract and Negligible for non-polar extract.
- ISO 10993-11:2017: Acute systemic toxicity study - No death or acute systemic toxicity was observed in the mice which received injection of the extract.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.6250 Non-powdered patient examination glove.
(a)
Identification. A non-powdered patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. A non-powdered patient examination glove does not incorporate powder for purposes other than manufacturing. The final finished glove includes only residual powder from manufacturing.(b)
Classification. Class I (general controls). The device, when it is a finger cot, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 880.9.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath.
January 26, 2024
Anhui Intco Medical Products Co., Ltd. Max Li Quality Specialist No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park Suixi County Huaibei City, Anhui 235000 China
Re: K233598
Trade/Device Name: Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs Regulation Number: 21 CFR 880.6250 Regulation Name: Non-Powdered Patient Examination Glove Regulatory Class: Class I. reserved Product Code: LZA, LZC, QDO, OPJ Dated: November 9, 2023 Received: November 9, 2023
Dear Max Li:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Allan Guan -S
For Bifeng Qian, M.D., Ph.D. Assistant Director
2
DHT4B: Division of Infection Control and Plastic and Reconstructive Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K233598
Device Name
Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentaryl Citrate, and Select Other Drugs
Indications for Use (Describe)
Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentaryl Citrate, and Select Other Drugs is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.
These gloves were tested for use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs as per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.
| Test Chemotherapy drug & Concentration | Minimum Breakthrough Detection Times (Minutes) |
|---|---|
| Bendamustine HCI; 5 mg/ml | >240 |
| Bleomycin sulfate; 15 mg/ml | >240 |
| Busulfan; 6 mg/ml | >240 |
| Carboplatin; 10 mg/ml | >240 |
| Carfilzomib; 2 mg/ml | >240 |
| Carmustine; 3.3 mg/ml | 1.7 |
| Cetuximab; 2 mg/ml | >240 |
| Cisplatin; 1 mg/ml | >240 |
| Cladribine; 1 mg/ml | >240 |
| Cyclophosphamide; 20 mg/ml | >240 |
| Cytarabine (Cytosine); 100 mg/ml | >240 |
| Cytovene (Ganciclovir); 10 mg/ml | >240 |
| Dacarbazine; 10 mg/ml | >240 |
| Daunorubicin HCL; 5 mg/ml | >240 |
| Decitabine; 5 mg/ml | >240 |
| Docetaxel; 20 mg/ml | >240 |
| Doxorubicin HCL; 2 mg/ml | >240 |
| Epirubicin HCL; 2 mg/ml | >240 |
| Etoposide; 20 mg/ml | >240 |
| Fludarabine Phosphate; 25 mg/ml | >240 |
| Fluorouracil; 50 mg/ml | >240 |
| Fulvestrant; 50 mg/ml | >240 |
| Gemcitabine HCI; 38 mg/ml | >240 |
| Idarubicin HCI; 1 mg/ml | >240 |
| Ifosfamide; 50 mg/ml | >240 |
| Irinotecan HCI; 20 mg/ml | >240 |
| Mechlorethamine HCL; 1 mg/ml | >240 |
| Melphalan HCI; 5 mg/ml | >240 |
| Methotrexate; 25 mg/ml | >240 |
| Mitomycin C; 0.5 mg/ml | >240 |
| Mitoxantrone HCI; 2 mg/ml | >240 |
| Oxaliplatin; 5 mg/ml | >240 |
| Paclitaxel; 6 mg/ml | >240 |
4
| Pemetrexed ; 25 mg/ml | >240 |
|---|---|
| Rituximab ; 10 mg/ml | >240 |
| ThioTepa ; 10 mg/ml | 0 |
| Topotecan HCL ; 1 mg/ml | >240 |
| Trisonex ; 1 mg/ml | >240 |
| Velcade (Bortezomib) ; 1 mg/ml | >240 |
| Vidaza (Azacytidine) ; 25 mg/ml | >240 |
| Vincrinstine Sulfate ; 1 mg/ml | >240 |
| Vinorelbine Tartrate, 10 mg/ml | >240 |
| Zoledronic Acid ; 0.8 mg/ml | >240 |
Please note that the following drugs have extremely low permeation times: Carmustine (BCNU): 1.7 minutes and Thiotepa:0 minute
Warning: Do not use with Carmustine and Thiotepa
| Fentanyl Citrate & Other Drugs | Minimum Breakthrough Detection Times |
|---|---|
| Fentanyl Citrate Injection(100 mcg/2ml) | >240 |
| Chloroquine ; 50mg/ml | >240 |
| Cyclosporin A; 100mg/ml | >240 |
| Retrovir ; 10 mg/ml | >240 |
| Type of Use (Select one or both, as applicable) |
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
5
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui Province, China
510(K)SUMMARY
(As required by 21 CFR 807.92) K233598
Date Prepared: Jan. 25. 2024
1. Owner's Identification:
Applicant Name: ANHUI INTCO MEDICAL PRODUCTS CO., LTD.
Location: No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui Province ,China
Contact Person: Max Li Tel: +86-18918364816
2. Name of the Device:
Trade / Product Name: Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs
Common Name: Exam Gloves Classification Name: Non-Powdered Patient Examination Glove Specialty Regulation: 21 CFR 880.6250 Product Code: LZA, LZC, QDO, OPJ Classification Panel: General Hospital Device Class: Class I
3. Predicate Device Information:
Better Care Plastic Technology Co., Ltd. Powder Free Nitrile Examination Glove (Grey) Tested for Use with Chemotherapy Drugs and Fentany) Citrate (K223713) Product code LZA, LZC, QDO, OPJ.
4. Device Description:
Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs are Class I Patient Examination Gloves and Specialty Chemotherapy Gloves. They are ambidextrous and come in different sizes - Extra Small, Small, Medium, Large, Extra Large, Extra Extra Large. Gloves meet the specification of ASTM D6319- 19 and have been tested for resistance to permeation by chemotherapy drugs, Fentanyl Citrate, and select other drugs as per ASTM D6978-05(2019). The gloves are single use, disposable, and provided non-sterile.
5. Indications for Use:
6
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui Province, China
K233598
Powder Free Nitrile Examination Glove 2.8 Blue Color, Non-Sterile, and Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.
These gloves were tested for use with Chemotherapy Drugs, Fentanyl Citrate, and Select Other Drugs as per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.
| Chemotherapy Drugs | Minimum Breakthrough Detection Time
(minutes) |
|--------------------------------------|--------------------------------------------------|
| Bendamustine HCl; 5 mg/ml | >240 min. |
| Bleomycin sulfate; 15 mg/ml | >240 min. |
| Busulfan; 6 mg/ml | >240 min. |
| Carboplatin; 10 mg/ml | >240 min. |
| Carfilzomib; 2 mg/ml | >240 min. |
| Carmustine; 3.3 mg/ml | 1.7 |
| Cetuximab; 2 mg/ml | >240 min. |
| Cisplatin; 1 mg/ml | >240 min. |
| Cladribine; 1 mg/ml | >240 min. |
| Cyclophosphamide; 20 mg/ml | >240 min. |
| Cytarabine (Cytosine); 100 mg/ml | >240 min. |
| Cytovene (Ganciclovir); 10 mg/ml | >240 min. |
| Dacarbazine; 10 mg/ml | >240 min. |
| Daunorubicin HCL; 5 mg/ml | >240 min. |
| Decitabine; 5 mg/ml | >240 min. |
| Docetaxel; 20 mg/ml | >240 min. |
| Doxorubicin HCl; 2 mg/ml | >240 min. |
| Epirubicin HCl; 2 mg/ml | >240 min. |
| Etoposide; 20 mg/ml | >240 min. |
| Fludarabine Phosphate; 25 mg/ml | >240 min. |
| Fluorouracil; 50 mg/ml | >240 min. |
| Fulvestrant; 50 mg/ml | >240 min. |
| Gemcitabine HCl; 38 mg/ml | >240 min. |
| Idarubicin HCl; 1 mg/ml | >240 min. |
| Ifosfamide; 50 mg/ml | >240 min. |
| Irinotecan HCl; 20 mg/ml | >240 min. |
| Mechlorethamine HCL; 1 mg/ml | >240 min. |
| Melphalan HCl; 5 mg/ml | >240 min. |
| Methotrexate; 25 mg/ml | >240 min. |
| Mitomycin C; 0.5 mg/ml | >240 min. |
| Mitoxantrone HCl; 2 mg/ml | >240 min. |
| Oxaliplatin;5 mg/ml | >240 min. |
| Paclitaxel; 6 mg/ml | >240 min. |
| Pemetrexed; 25 mg/ml | >240 min. |
| Rituximab; 10 mg/ml | >240 min. |
| Thio Tepa; 10 mg/ml | 0 |
| Topotecan HCl; 1 mg/ml | >240 min. |
| Trisenox (Arsenic Trioxide); 1 mg/ml | >240 min. |
| Velcade (Bortezomib); 1 mg/ml | >240 min. |
| Vidaza (Azacytidine); 25mg/ml | >240 min. |
| Vincristine Sulfate; 1 mg/ml | >240 min. |
| Vinorelbine Tartrate; 10 mg/ml | >240 min. |
| Zoledronic Acid; 0.8 mg/ml | >240 min. |
Table 1
7
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui Province, China
*Please note that the following drugs have extremely low permeation times:
Carmustine: 1.7 minutes, Thio Tepa: 0 minutes
Warning: Do not use with Carmustine and Thio Tepa.
| Fentanyl Citrate & Other Drugs | Minimum Breakthrough Detection Time
(minutes) |
|-----------------------------------------|--------------------------------------------------|
| Fentanyl Citrate Injection(100 mcg/2ml) | >240 min. |
| Chloroquine; 50mg/ml | >240 min. |
| Cyclosporin A; 100mg/ml | >240 min. |
| Retrovir; 10 mg/ml | >240 min. |
6. Comparison of Subject Device and Predicate Device:
The following tables are summaries of the technological characteristics, biocompatibility and
performance testing of the proposed and predicate devices. General Comparison Table:
| Device | Proposed Device | Predicate Device | Comparison |
|---|---|---|---|
| 510K # | K233598 | K223713 | - |
| Product Name | Powder Free Nitrile Examination | ||
| Glove 2.8 Blue Color, Non-Sterile, | |||
| and Tested for Use with | |||
| Chemotherapy Drugs, Fentanyl | |||
| Citrate, and Select Other Drugs | Powder Free Nitrile Examination | ||
| Glove (Grey) Tested for Use with | |||
| Chemotherapy Drugs and Fentanyl | |||
| Citrate | - | ||
| Product Code | LZA, LZC, QDO, OPJ | LZA, LZC, QDO, OPJ | Same |
| Regulation | |||
| Number | 21 CFR 880.6250 | 21 CFR 880.6250 | Same |
| Indications for | |||
| use | Powder Free Nitrile Examination | ||
| Glove 2.8 Blue Color, Non-Sterile, | |||
| and Tested for Use with | |||
| Chemotherapy Drugs, Fentanyl | |||
| Citrate, and Select Other Drugs is a | |||
| disposable device intended for | |||
| medical purposes that is worn on the | |||
| examiner's hand or finger to prevent | |||
| contamination between patient and | |||
| examiner. | |||
| These gloves were tested for use | |||
| with Chemotherapy Drugs, | |||
| Fentanyl Citrate, and Select Other | |||
| Drugs as per ASTM D6978-05 | |||
| (Reapproved 2019) Standard | |||
| Practice for Assessment of | The glove is a disposable device | ||
| intended for medical purposes that is | |||
| worn on the examiner's hand to | |||
| prevent contamination between | |||
| patient and examiner. Gloves have | |||
| been tested for use with chemotherapy | |||
| drugs and Fentanyl Citrate. | Same |
8
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui Province, China
| | Medical Gloves to Permeation by
Chemotherapy Drugs. | | |
|-----------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------|-----------|
| Powder free | Yes | Yes | Same |
| Design feature | Ambidextrous | Ambidextrous | Same |
| Material | Nitrile | Nitrile | Same |
| Color | Blue | Grey | Different |
| Size | XS, S, M, L, XL, XXL | XS, S, M, L, XL | Different |
| Sterile | Non-Sterile | Non-Sterile | Same |
| Use | Single use | Single use | Same |
| Chemotherapy
Drugs,
Fentanyl
Citrate, and
Select Other
Drugs Claim | See below comparison table | See below comparison table | Similar |
Analysis: The proposed device has size XS, S, M, L, XL, XXL and Blue color, while the predicate device has size XS, S, M, L, XL and Grey color. But safety and performance testing has been done to the proposed device and the results showed that the device meets the requirements of standard ASTM D6319-19. Therefore, this difference does not raise any new safety or performance questions.
Technological Characteristic and Biocompatibility Comparison Table:
| Item | Standard | Proposed device | Predicate device K223713 | Result |
|---|---|---|---|---|
| Dimension | ASTM D6319-19 | Minimum 220mm for size | ||
| XS and S, | ||||
| 230mm for size M, L, XL | ||||
| Width(mm): | ||||
| XS: 70±10 | ||||
| S: 80±10 | ||||
| M: 95±10 | ||||
| L: 110±10 | ||||
| XL: 120±10 | ||||
| XXL: 130±10 | ||||
| Thickness(mm): | ||||
| Palm: Minimum 0.05 | ||||
| Finger: Minimum 0.05 | Length: Min 230mm | |||
| Width(mm): | ||||
| XS: 70±10 | ||||
| S: 80±10 | ||||
| M: 95±10 | ||||
| L: 110±10 | ||||
| XL: 120±10 | ||||
| XXL: / | ||||
| Thickness:(mm) | ||||
| Palm: Minimum 0.05 | ||||
| Finger: Minimum 0.05 | Similar | |||
| Physical properties | ||||
| Before aging | ||||
| Tensile strength | ||||
| Ultimate elongation | ||||
| After aging | ||||
| Tensile strength | ||||
| Ultimate elongation | ASTM D6319-19 | |||
| ASTM D412-16 | 14MPa, min | |||
| 500%, min | ||||
| 14MPa, min | ||||
| 400%, min | 14MPa, min | |||
| 500%, min | ||||
| 14MPa, min | ||||
| 400%, min | Same |
9
No. 6, Haitang South Road, Suixi Wedical Products Co.,Ltd.
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui
Province, Province,
vince, China
| Freedom from holes | ASTM D6319-19
ASTM D5151-19 | G-I, AQL2.5 | G-I, AQL2.5 | Same |
|--------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|------------|
| Residual Powder | ASTM D6319-19
ASTM D6124-06 | ≤2 mg per glove | ≤2 mg per glove | Same |
| Biocompatibility | Irritation
ISO 10993-23 | Under the conditions of this
study, the irritation response
category of the test article is
classified as Negligible for
polar extract and Negligible
for non-polar extract. | Based on the criteria, the test
article extracts were
considered negligible irritants. | Similar(1) |
| | Sensitization ISO
10993-10 | The sample extract elicits no
sensitization reactions under
the test conditions | Based on the criteria and
conditions of the study, the
test article is classified as a
non-sensitizer | Similar |
| | Acute Systemic
Toxicity Test ISO
10993 -11 | No death or systemic toxicity
was observed in the mice
which received injection of
the extract | Based on the criteria, the test
article meets the
requirements | Similar |
- The new version of standard for Skin Irritation we refer is ISO 10993-23:2021, the test method and process is the old version ISO 10993-10
Chemotherapy Permeation, Fentanyl Citrate, and Select Other Drugs Comparison Claim:
| Chemotherapy Drugs, Fentanyl Citrate,
| and Select Other Drugs | Minimum BDT (Minutes) | ||
|---|---|---|---|
| Proposed device | Predicate device | ||
| K223713 | Remark | ||
| Bendamustine HCI ; 5 mg/ml | >240 min. | >240 min. | Same |
| Bleomycin sulfate ; 15 mg/ml | >240 min. | >240 min. | Same |
| Busulfan ; 6 mg/ml | >240 min. | >240 min. | Same |
| Carboplatin; 10 mg/ml | >240 min. | >240 min. | Same |
| Carfilzomib ; 2 mg/ml | >240 min. | >240 min. | Same |
| Carmustine ; 3.3 mg/ml | 1.7 | 13.9 | Different* |
| Cetuximab ; 2 mg/ml | >240 min. | >240 min. | Same |
| Chloroquine ; 50mg/ml | >240 min. | -- | Different* |
| Cisplatin ; 1 mg/ml | >240 min. | >240 min. | Same |
| Cladribine ; 1 mg/ml | >240 min. | -- | Different* |
| Cyclophosphamide; 20 mg/ml | >240 min. | >240 min. | Same |
| Cyclosporin A; 100mg/ml | >240 min. | -- | Different* |
| Cytarabine (Cytosine) ; 100 mg/ml | >240 min. | >240 min. | Same |
| Cytovene (Ganciclovir); 10 mg/ml | >240 min. | >240 min. | Same |
| Dacarbazine ; 10 mg/ml | >240 min. | >240 min. | Same |
| Daunorubicin HCL; 5 mg/ml | >240 min. | >240 min. | Same |
| Decitabine ; 5 mg/ml | >240 min. | >240 min. | Same |
| Docetaxel ; 20 mg/ml | >240 min. | >240 min. | Same |
| Province, China | |||
| K233598 | |||
| Doxorubicin HCL ; 2 mg/ml | >240 min. | >240 min. | Same |
| Epirubicin HCL ; 2 mg/ml | >240 min. | >240 min. | Same |
| Etoposide ; 20 mg/ml | >240 min. | >240 min. | Same |
| Eribulin Mesylate; 0.5 mg/ml | -- | >240 min. | Different* |
| Fludarabine Phosphate; 25 mg/ml | >240 min. | >240 min. | Same |
| Fluorouracil ; 50 mg/ml | >240 min. | >240 min. | Same |
| Fulvestrant ; 50 mg/ml | >240 min. | >240 min. | Same |
| Gemcitabine HCI ; 38 mg/ml | >240 min. | >240 min. | Same |
| Idarubicin HCI ; 1 mg/ml | >240 min. | >240 min. | Same |
| Ifosfamide ; 50 mg/ml | >240 min. | >240 min. | Same |
| Irinotecan HCI ; 20 mg/ml | >240 min. | >240 min. | Same |
| Mechlorethamine HCL; 1 mg/ml | >240 min. | >240 min. | Same |
| Melphalan HCI; 5 mg/ml | >240 min. | >240 min. | Same |
| Methotrexate ; 25 mg/ml | >240 min. | >240 min. | Same |
| Mitomycin C ; 0.5 mg/ml | >240 min. | >240 min. | Same |
| Mitoxantrone HCI ; 2 mg/ml | >240 min. | >240 min. | Same |
| Oxaliplatin ;5 mg/ml | >240 min. | >240 min. | Same |
| Pacilitaxel ; 6 mg/ml | >240 min. | >240 min. | Same |
| Pemetrexed ; 25 mg/ml | >240 min. | >240 min. | Same |
| Pertuzumab; 30 mg/ml | -- | >240 min. | Different* |
| Raltitrexed monohydrate | -- | >240 min. | Different* |
| Retrovir ; 10 mg/ml | >240 min. | >240 min. | Same |
| Rituximab ; 10 mg/ml | >240 min. | >240 min. | Same |
| Temsirolimus ; 25mg/ml | -- | >240 min. | Different* |
| ThioTEPA ; 10 mg/ml | 0 | 44.4 | Different* |
| Topotecan HCL ; 1 mg/ml | >240 min. | >240 min. | Same |
| Trastuzumab ; 21mg/ml | -- | >240 min. | Different* |
| Trisenox (Arsenic Trioxide); 1 mg/ml | >240 min. | >240 min. | Same |
| Velcade (Bortezomib); 1 mg/ml | >240 min. | >240 min. | Same |
| Vidaza (Azacytidine); 25mg/ml | >240 min. | >240 min. | Same |
| Vinblastine ; 1mg/ml | -- | >240 min. | Different* |
| Vincristine Sulfate ; 1 mg/ml | >240 min. | >240 min. | Same |
| Vinorelbine Tartrate; 10 mg/ml | >240 min. | >240 min. | Same |
| Zoledronic Acid ; 0.8 mg/ml | >240 min. | >240 min. | Same |
| Fentanyl; 100mcg/2ml | >240 min. | >240 min. | Same |
| Simulated Gastric Acid | -- | -- | -- |
| Fluid/Fentanyl Citrate Injection Mix | |||
| 50/50 Solution | -- | >240 min. | Different* |
10
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui
Province, China
- Chemotherapy drugs and the minimum breakthrough time of subject device will be listed on labeling, so this difference does not raise questions of safety and effectiveness.
7. Summary of Non-Clinical Performance Data
11
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Huaibei City, Anhui
Province, China
Non-clinical tests were conducted to verify that the proposed device met all design specifications. The test results demonstrated that the proposed device met the performance criteria with the following standards:
| Methodology | Test Performed | Acceptance Criteria | Results | ||
|---|---|---|---|---|---|
| ASTM D6319-19 | Physical Dimensions | ||||
| Length | Minimum 220mm for size XS | ||||
| and S, 230mm for size M, L, XL | Pass | ||||
| ASTM D6319-19 | Physical Dimensions Palm | ||||
| Width | XS: 70±10mm | ||||
| S: 80±10mm | |||||
| M: 95±10mm | |||||
| L:110±10mm | |||||
| XL: 120±10mm | |||||
| XXL: 130±10mm | Pass | ||||
| ASTM D6319-19 | Physical Dimensions | ||||
| Thickness | Finger: 0.05mm (min) | ||||
| Palm: 0.05mm (min) | Pass | ||||
| ASTM D6319-19 | |||||
| ASTM D412-16 (2021) | Physical Properties | Before aging: 14MPa, min | |||
| 500%, min | |||||
| After aging: 14MPa, min | |||||
| 400%, min | Pass | ||||
| ASTM D6319-19 | |||||
| ASTM D5151-19 | Water leak test | G-I, AQL 2.5 (ISO 2859-1) | Pass | ||
| ASTM D6319-19 | |||||
| ASTM D6124-06 (2017) | Powder Residue | Max 2mg/glove | |||
| ASTM D6978-05 (2019) | Permeation by | ||||
| Chemotherapy Drugs | |||||
| and Fentanyl Citrate | Refer the above table 1 | ||||
| ISO 10993-10:2021 | Skin Sensitization | No Skin sensitization | The sample extract | ||
| elicits no sensitization | |||||
| reactions under the | |||||
| test conditions | |||||
| ISO 10993-23:2021 | Irritation | No Skin irritation | Under the conditions | ||
| of this study, the | |||||
| irritation response | |||||
| category of the test | |||||
| article is classified as | |||||
| Negligible for polar | |||||
| extract and Negligible | |||||
| for non-polar extract. | |||||
| ISO 10993-11:2017 | Acute systemic toxicity | ||||
| study | Subject showed no adverse | ||||
| biological reaction | No death or acute systemic | ||||
| toxicity was observed | |||||
| in the mice which | |||||
| received injection of | |||||
| the extract |
12
No. 6, Haitang South Road, Suixi Wuhu Modern Industrial Park, Suixi County, Hualbei City, Anhui Province, China
K233598
ASTM D6319- 19, Standard Specification for Nitrile Examination Gloves for Medical Application. .
- ASTM D5151-19, Standard Test Method for Detection of Holes in Medical Gloves.
- ASTM D6124-06 (Reapproved 2017), Standard Test Method for Residual Powder on Medical Gloves
ASTM D412-16 (2021) Standard Test Methods for Vulcanized Rubber and Thermoplastic Elastomers— Tension
ASTM D6978-05 (Reapproved 2019), Assessment of Reissuance of Medical Gloves to Permeation by Chemotherapy Drugs.
- ISO 10993-10: 2021 Biological evaluation of medical devices Part 10: Tests for skin sensitization.
- ISO 10993-23:2021 Biological evaluation of medical devices Part 23 : Tests for irritation.
- ISO 10993-11:2017 Biological evaluation of medical devices Part 11: Tests for systemic toxicity
8. Summary of Clinical Testing:
Not provided for the subject device.
9. Conclusion:
The conclusions drawn from the non-clinical tests demonstrate that the subject device is as safe, as effective, and performs as well as or better than the legally marketed predicate device, K223713, Powder Free Nitrile Examination Glove (Grey) Tested for Use with Chemotherapy Drugs and Fentanyl Citrate.